Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Bullous Pemphigoid
NCT04117932Phase 2Completed
- Sponsor
- CHU de Reims
- Start
- Mar 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ustekinumab in Bullous Pemphigoid (BP), sponsored by CHU de Reims. Started Mar 2020; status: completed.
02
Drugs
ustekinumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT04117932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04117932.